New Aspects in the Management of Hypertension in Patients with Chronic Kidney Disease not on Renal Replacement Therapy.

High Blood Press Cardiovasc Prev · 2022 · PMC8942929 · PMID 34910287

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

more or less significantno p-value reported

Positive results came from the use of sitaxsentan, atrasentan, avosentan and sparsentan with significant proteinuria reductions observed when compared to RAS blockers or on top of RAS inhibitors with more or less significant reductions in BP [ 97 – 99 ].

also in 311 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.